A comparison of Regeneron Pharmaceuticals and Illumina reveals differing valuations and growth prospects.
In the competitive landscape of the pharmaceuticals and biotechnology sector, Regeneron Pharmaceuticals Inc. (REGN) and Illumina Inc. (ILMN) stand out as significant players. Both companies have received positive ratings from analysts, but their financial metrics suggest different valuations. This analysis will look at their price-to-earnings (P/E), price/earnings to growth (PEG), and price-to-book (P/B) ratios to see which stock might be a better value for investors.
Investor takeaway: While Regeneron appears cheaper on several key valuation multiples, this doesn’t necessarily mean it’s a better investment. Factors like growth potential, market conditions, and company-specific developments should also be considered.
Advertisement
Stocks in this list
Live snapshots — open any name for the full quote and Wealth Awesome price forecast.
Regeneron Pharmaceuticals Inc
REGN.US
Health Care
$762.81
$76.86B
1D
+2.18%
1W
+5.00%
Illumina Inc
ILMN.US
Health Care
$276.67
$41.78B
1D
-0.54%
1W
-5.80%
Advertisement
Valuation Metrics Comparison
Regeneron shows a more attractive valuation with a P/E of 18.5, PEG of 1.32, and P/B of 2.41 compared to Illumina's P/E of 51.6, PEG of 3.05, and P/B of 14.72.
Advertisement
Bull case
Regeneron’s lower P/E of 18.5 compared to Illumina's 51.6 suggests a more appealing entry point for investors. With a PEG of 1.32, Regeneron indicates potential for growth that aligns well with its earnings. This could attract value-focused investors looking for solid returns.
Bear case
On the other hand, Illumina's higher P/E and PEG ratios may reflect its strong growth prospects, especially in the genomics field. The company’s return on equity (ROE) of 32.3% is significantly higher than Regeneron's 14.0%, indicating that Illumina is generating more profit per dollar of equity. This could justify its higher valuation for growth-oriented investors.
Market Position and Analyst Consensus
Both companies are well-regarded in the healthcare sector, with analysts recommending a 'Buy' for each. Regeneron has an analyst target of US$859.04, suggesting significant upside potential from its current price of US$762.81. In contrast, Illumina's target of US$233.55 reflects a more cautious outlook given its current price of US$276.67. These targets highlight differing market sentiments and growth expectations for each company.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
